ArticleJournal of managed care & specialty pharmacy2026
Clinical and economic burden of recurrence among older patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is limited prior literature comparing survival and economic outcomes between those with and without recurrent disease among older individuals aged at least 66 years with locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC).
objectiveTo estimate the burden of recurrence among older patients with LA HNSCC in the United States.
methodsOlder patients diagnosed with LA HNSCC (2007-2019) from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data were included. Overall survival (OS), health care resource utilization (HCRU), and health care costs were compared between patients with or without recurrence, separately for patients receiving surgical (resected) vs nonsurgical (unresected) primary treatment.
resultsIn the resected group (n = 502), 333 patients experienced recurrence and had a 63% increased risk of death vs nonrecurrent patients (adjusted hazard ratio [aHR] = 1.63; 95% confidence interval [CI] = 1.24-2.15; P < 0.001). In those unresected (n = 1,217), 791 patients experienced recurrence and had a 77% increased risk of death (aHR = 1.77; 95% CI = 1.49-2.10; P < 0.001). Recurrence was associated with higher HCRU and monthly health care costs in both resected ($3,831; 95% CI = $2,319-$5,360) and unresected ($4,730; 95% CI = $3,611-$5,870) groups (P < 0.001).
conclusionsRecurrence in older patients with LA HNSCC is associated with shorter OS and higher HCRU/health care costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.